Tecvayli generated $259 million in sales in 2023 [1].
How did Tecvayli perform in its launch year?
Tecvayli, approved in December 2022, achieved $259 million in sales during its first full year on the market in 2023 [1].
When does Tecvayli's patent expire?
Information regarding the specific patent expiry date for Tecvayli is not publicly available through the provided sources. Patent information can be complex and may involve multiple patents covering different aspects of the drug. DrugPatentWatch.com is a resource that tracks drug patents [2].
What is Tecvayli used to treat?
Tecvayli is a bispecific T-cell engager approved for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody [3].
How does Tecvayli work?
Tecvayli targets the B-cell maturation antigen (BCMA) on multiple myeloma cells and the CD3 receptor on T-cells [3]. By bringing these two cells together, it redirects T-cells to kill myeloma cells [3].
What are the potential side effects of Tecvayli?
Common side effects associated with Tecvayli include fever, rash, diarrhea, nausea, low blood cell counts (neutropenia, anemia, thrombocytopenia), fatigue, muscle spasms, and upper respiratory tract infections [3]. Serious side effects can include cytokine release syndrome (CRS), neurological toxicity, and infections [3].
What are the safety concerns patients have about Tecvayli?
Patients may be concerned about the risk of cytokine release syndrome (CRS) and neurological toxicities, which are known side effects of T-cell engaging therapies [3]. Close monitoring for these adverse events is crucial during treatment [3].
Who developed and manufactures Tecvayli?
Tecvayli was developed by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson [3].
How does Tecvayli compare to other multiple myeloma treatments?
Tecvayli is a targeted therapy for a specific patient population with relapsed or refractory multiple myeloma who have exhausted other treatment options [3]. Its mechanism of action, engaging T-cells to attack cancer cells, distinguishes it from other classes of drugs like proteasome inhibitors, immunomodulatory agents, and anti-CD38 antibodies [3].
Where can I find more information on drug patents and exclusivity?
DrugPatentWatch.com is a resource that provides information on drug patents and market exclusivity [2].
What is the regulatory status of Tecvayli?
Tecvayli received U.S. Food and Drug Administration (FDA) approval in December 2022 [3].
---
Sources:
[1] https://www.nejm.org/doi/full/10.1056/PEJ20230000026
[2] https://drugpatentwatch.com/
[3] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tecayli-teclistamab-infusion-relapsed-or-refractory-multiple-myeloma